Conferences - Results from #340

Viewing 341-360 of 11775 articles

ASCO 2024: Cost-Effectiveness Analysis of Contemporary First-Line Agents in Locally Advanced/metastatic Urothelial Carcinoma

ASCO 2024: Considerations in Treating and Palliating Variant Genitourinary Cancers Where No Standard of Care Exists

ASCO 2024: Age and Other Criteria Influencing Non-Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries

ASCO 2024: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC

ASCO 2024: Avelumab First Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Histological Subtypes

ASCO 2024: Prognostic Impact of Residual Cancer Burden on Long-Term Outcomes After Neoadjuvant Androgen Receptor Pathway Inhibitor and Radical Prostatectomy for High-Risk Localized Prostate Cancer: A Pooled Analysis of Phase 2 Trials

ASCO 2024: Patient-Centered Approaches to Improve Quality of Life and Mitigate the Adverse Effects of Androgen Deprivation Therapy

ASCO 2024: Debunking the Frailty-Sarcopenia-ADT Axis in Metastatic Prostate Cancer with Multicomponent Exercise: The FIERCE Trial

ASCO 2024: A Phase II Trial of Enzalutamide with 5-Alpha Reductase Inhibitors as an ADT–Sparing Approach for Older Men with CSPC

ASCO 2024: Bone Resorptive Agents and Their Appropriate Use and Timing

ASCO 2024: Impact of Alterations in Tumor Suppressor Genes on Survival Outcomes in Patients with De Novo mCSPC Cancer Receiving ADT with ARPI or Docetaxel

ASCO 2024: Discussion: The Needle in the Haystack: Finding Biomarkers in Kidney Cancer

ASCO 2024: Discussion: Tailoring Treatment and Navigating Patient Preferences

ASCO 2024: ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Spaces

ASCO 2024: ARV-766, a PROTAC Androgen Receptor Degrader, in mCRPC: Initial Results of a Phase 1/2 Study

ASCO 2024: Prognostic PSMA-PET PROMISE Nomograms for Patients with Prostate Cancer

ASCO 2024: A Phase 1 Study of JNJ-69086420 (JNJ-6420), an Actinium-225 (225Ac)-Labeled Antibody Targeting Human Kallikrein 2, for mCRPC

ASCO 2024: Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer

ASCO 2024: Blood-Based Markers of Differential Efficacy of Bipolar Androgen Therapy and Enzalutamide in the Randomized TRANSFORMER Trial

ASCO 2024: DeLLpro-300: Phase 1b Study of Tarlatamab in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer

13
14
15
16
17
18
19
20
21
22